PARP1i BMN673 combined with FLT3i AC220 inhibited the growth in FLT3(ITD)-positive AML primary cells in mice and reduced the number of LSCs. (A) Experimental design. (B) Mean percentage of hCD45⁺ cells ± SD in peripheral blood cells (PBL, n = 5-6) and bone marrow cells (BMC, n = 3-5). *P < .01, **P = .002 vs individual treatment, Student t test and response additivity approach, respectively. (C) Survival curves and MST of mice bearing a primary AML xenograft and treated as indicated (n = 6-10 mice per group). (D) Survival curves and MST of secondary transplant mice. *P ≤ .002 vs individual treatments, Kaplan-Meier log-rank test.